Posters

Subconjuctival anti-VEGF (bevacizumab) to reduce pterygium recurrence

Poster Details

First Author: E.Abdel-Azim EGYPT

Co Author(s):                        

Abstract Details

Purpose:

To evaluate and investigate the effect of subconjuctival injection of anti-VEGF (Bevacizumab) to prevent recurrence of pterygium.

Setting:

Eye Unit, Golf Specialised Hospital & Clinics, Cairo, Egypt.

Methods:

Twenty patients (mean age 33 +/- 4 year old, women were 25% and Egyptian ancestry was 100% of the cases) with 20 eyes with primary pterygium were included in this work. Exclusion criteria included recurrent pterygium or any other corneal and/or conjuctival diseases. Patients underwent pterygium excision with local anesthesia and intraoperative subconjuctival 0.1 mL (1 mg) anti-VEGF (Bevacizumab). The main outcome investigated was the recurrence of pterygium and corneal vascularization at any time during postoperative follow-up.

Results:

The 20 eyes of the 20 patients were followed up for an average of 6 +/- 3 months. Recurrence of pterygium and corneal vascularization in 1 eye (5 %).

Conclusions:

In this work, it was clear that intraoperative subconjunctival anti-VEGF (Bevacizumab) has influenced the frequency of non-recurrence of pterygium and corneal vascularization after primary pterygium surgical excision. Further works and investigations will also be needed.

Financial Disclosure:

NONE